Search
Close this search box.

Sanofi Initiates Clinical Trials for Experimental Acne Vaccine

Paris:French pharmaceutical company Sanofi is actively recruiting adults aged 18 to 45 for clinical studies to evaluate an experimental mRNA vaccine aimed at treating acne.

According to Anadolu Agency – English, the trials are designed to assess both mild and moderate to severe acne. Sanofi's studies integrate phase 1 and phase 2 research to evaluate the safety of the vaccine candidate, the immune response it generates, and its effectiveness in improving acne conditions.

One of the studies, registered as NCT06316297, plans to enroll 800 participants with moderate to severe acne. Researchers will test up to four dose levels, and participants will receive either two or three intramuscular injections depending on their assigned study group. This study aims to identify an optimal dose and vaccination schedule for future efficacy trials.

A second study, registered as NCT07013747, targets 228 participants with mild acne. This study will administer two injections at a single dose level and initially conduct stepwise safety assessments on a preliminary group before involving the main group. The study includes optional long-term follow-up, with some participants monitored for up to 30 months after their final core-study visit to evaluate longer-term effects.

The investigational vaccine trials aim to establish whether the vaccine can provide a safe and effective treatment for acne sufferers, a chronic inflammatory skin condition prevalent among adolescents and young adults. Current treatments generally focus on controlling lesions, reducing flare-ups, and preventing scarring.